GUCY2C Molecular Staging Personalizes Colorectal Cancer Patient Management

Overview

Journal Biomark Med

Specialties Biochemistry
General Medicine

Date 2012 Jun 27

PMID 22731908

Citations 3

Authors

Jian P Gong

Stephanie Schulz

Terry Hyslop

Scott A Waldman

Affiliations

Soon will be listed here.

Abstract

While the most significant prognostic and predictive marker in the management of colorectal cancer patients is cancer cells in regional lymph nodes, approximately 30% of patients whose lymph nodes are ostensibly free of tumor cells by histopathology ultimately develop recurrent disease reflecting occult metastases. Molecular techniques utilizing highly specific markers and ultra-sensitive detection technologies have emerged as powerful staging platforms to establish prognosis and predict responsiveness to chemotherapy in colorectal cancer patients. This review describes the evolution of the tumor suppressor GUCY2C as a prognostic and predictive molecular biomarker that quantifies occult tumor burden in regional lymph nodes for staging patients with colorectal cancer.

Citing Articles

GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

Lisby A, Flickinger Jr J, Bashir B, Weindorfer M, Shelukar S, Crutcher M Expert Rev Precis Med Drug Dev. 2021; 6(2):117-129.

PMID: 34027103 PMC: 8133521. DOI: 10.1080/23808993.2021.1876518.

CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.

Zhang Q, Zhang Z, Peng M, Fu S, Xue Z, Zhang R Oncoimmunology. 2017; 5(12):e1251539.

PMID: 28123893 PMC: 5214859. DOI: 10.1080/2162402X.2016.1251539.

A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.

Xia J, Jia P, Hutchinson K, Dahlman K, Johnson D, Sosman J Mol Cancer Ther. 2014; 13(7):1918-28.

PMID: 24755198 PMC: 4090262. DOI: 10.1158/1535-7163.MCT-13-0804.

References

Shailubhai K, Yu H, Karunanandaa K, Wang J, Eber S, Wang Y . Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 2000; 60(18):5151-7. View

Abati A, Liotta L . Looking forward in diagnostic pathology: the molecular superhighway. Cancer. 1996; 78(1):1-3. DOI: 10.1002/(SICI)1097-0142(19960701)78:1<1::AID-CNCR1>3.0.CO;2-S. View

Rao M, Guandalini S, Smith P, Field M . Mode of action of heat-stable Escherichia coli enterotoxin. Tissue and subcellular specificities and role of cyclic GMP. Biochim Biophys Acta. 1980; 632(1):35-46. DOI: 10.1016/0304-4165(80)90247-0. View

Carrithers S, Parkinson S, Goldstein S, Park P, ROBERTSON D, Waldman S . Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology. 1994; 107(6):1653-61. DOI: 10.1016/0016-5085(94)90804-4. View

Wolpin B, Meyerhardt J, Mamon H, Mayer R . Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007; 57(3):168-85. DOI: 10.3322/canjclin.57.3.168. View

Lin J, Li P, Pitari G, Schulz S, Waldman S . Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncol. 2009; 5(4):509-22. PMC: 2749695. DOI: 10.2217/fon.09.14. View

Waldman S, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J . Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA. 2009; 301(7):745-52. PMC: 2756012. DOI: 10.1001/jama.2009.141. View

Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek M . A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res. 2006; 12(15):4545-52. DOI: 10.1158/1078-0432.CCR-06-0865. View

Field M, Graf Jr L, Laird W, Smith P . Heat-stable enterotoxin of Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine. Proc Natl Acad Sci U S A. 1978; 75(6):2800-4. PMC: 392652. DOI: 10.1073/pnas.75.6.2800. View

10.

Amstutz U, Carleton B . Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther. 2011; 89(6):924-7. DOI: 10.1038/clpt.2011.18. View

11.

Waldman S, Cagir B, Rakinic J, Fry R, Goldstein S, Isenberg G . Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis Colon Rectum. 1998; 41(3):310-5. DOI: 10.1007/BF02237484. View

12.

Notterman D, Alon U, Sierk A, Levine A . Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 2001; 61(7):3124-30. View

13.

Pitari G, Li P, Lin J, Zuzga D, Gibbons A, Snook A . The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther. 2007; 82(4):441-7. DOI: 10.1038/sj.clpt.6100325. View

14.

Sobrero A, Kerr D, Glimelius B, Van Cutsem E, Milano G, Pritchard D . New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer. 2000; 36(5):559-66. DOI: 10.1016/s0959-8049(99)00314-7. View

15.

Wilson C, Schultz S, Waldman S . Where medicine, business, and public policy intersect. Biotechnol Healthc. 2013; 4(1):33-42. PMC: 3564384. View

16.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

17.

Paugh S, Stocco G, McCorkle J, Diouf B, Crews K, Evans W . Cancer pharmacogenomics. Clin Pharmacol Ther. 2011; 90(3):461-6. PMC: 3646359. DOI: 10.1038/clpt.2011.126. View

18.

Compton C, Greene F . The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004; 54(6):295-308. DOI: 10.3322/canjclin.54.6.295. View

19.

Guarino A, Cohen M, Overmann G, Thompson M, Giannella R . Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig Dis Sci. 1987; 32(9):1017-26. DOI: 10.1007/BF01297193. View

20.

Steinbrecher K, Tuohy T, Heppner Goss K, Scott M, Witte D, Groden J . Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem Biophys Res Commun. 2000; 273(1):225-30. DOI: 10.1006/bbrc.2000.2917. View